目的：观察程序性死亡蛋白配体1（PDL1）和Ki67在三阴性乳腺癌中的表达及与临床病理因素的相关性。方法：应用免疫组织化学法检测151例三阴性乳腺癌、137例非三阴性乳腺癌、48例正常乳腺组织中PDL1和Ki67的蛋白表达情况，结合临床病理资料综合分析其临床意义。结果： PDL1和Ki67分别在乳腺癌细胞的细胞质和细胞核表达。在151例三阴性乳腺癌中PDL1阳性表达98例（64.90%），阳性率高于非三阴性乳腺癌（χ²=5.633，P<0.05）和正常乳腺组织（χ²=106.471，P<0.001），Ki67阳性表达121例（80.13%），阳性率高于非三阴性乳腺癌（χ²=4.460，P<0.05）和正常乳腺组织（χ²=154.717，P<0.001），差异有统计学意义。在三阴性乳腺癌组织中，PDL1阳性较PDL1阴性患者组织学分级高、伴淋巴结转移与远处转移的多，差异有统计学意义（均P<0.05），患者年龄、肿块大小、是否绝经组间差异均无统计学意义（均P>0.05）；Ki67阳性患者较Ki67阴性患者组织学分级高、伴淋巴结转移与远处转移的多，差异有统计学意义（均P<0.05），患者年龄、肿块大小、是否绝经组间差异均无统计学意义（均P>0.05）。结论：检测PDL1和Ki67对判断三阴性乳腺癌发展和预后有一定价值。

[1] JACQUES F, MURIELLE C, ISABELLE S, et al.Cancer statistics for the year 2020:an overview[J].Int J Can, 2021,[Online ahead of print].
[2] 王丽娜, 张崇建, 李连方, 等.三阴性乳腺癌表柔比星和环磷酰胺联合紫杉醇周疗新辅助化疗临床观察[J].中华肿瘤防治杂志, 2015, 22(3):211-215.
[3] MILLIS S Z, GATALICA Z, WINKLER J, et al.Predictive biomarker profiling of >6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications[J].Clin Breast Cancer, 2015, 15(6):473-481.
[4] LI C Y, ZHANG S, ZHANG X B, et al.Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients:a retrospective study[J].Asian Pac J Cancer Prev, 2013, 14(6):3779-3784.
[5] SHARMA P, ALLISON J P.The future of immune checkpoint therapy[J].Science, 2015, 348(6230):56-61.
[6] 兰芬, 李睿旻, 阳凌燕, 等.程序性细胞死亡蛋白1及其配体抑制剂抗肿瘤免疫治疗进展[J].国际药学研究杂志, 2016, 43(5):813-817.
[7] MARTÍNEZ-ARRIBAS F, NÚÑEZ M J, PIQUERAS V, et al.Flow cytometry Ki67 labelling index in breast cancer:a prospective evaluation of 181 cases[J].Anticancer Res, 2002, 22(1A):295-298.
[8] 夏婷.TK1、Ki67在乳腺癌中的表达及其临床意义[D].长沙:中南大学, 2008.
[9] KONISHI J, YAMAZAKI K, AZUMA M, et al.B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J].Clin Cancer Res, 2004, 10(15):5094-5100.
[10] RADZIEWICZ H, IBEGBU C C, FERNADEZ M L, et al.Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression[J].J Virol, 2007, 81(6):2545-2553.
[11] ARASANZ H, GATO-CANAS M, ZUAZO M, et al.PD1 signal transduction pathways in T cells[J].Oncotarget, 2017, 8(31):51936-51945.
[12] 张蝶, 高雅茹, 刘丽, 等.PD-L1/PD-1在三阴性乳腺癌中的研究进展[J].肿瘤学杂志, 2019, 25(11):947-951.
[13] EMENS L A.Breast cancer immunotherapy:facts and hopes[J].Clin Cancer Res, 2018, 24(3):511-520.
[14] HUANG X, XIE X, WANG H, et al.PDL1 and LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a[J].J Exp Clin Cancer Res, 2017, 36(1):129.
[15] MEGO M, REUBEN J M.Emerging predictive biomarkers of response to platinum therapy in triple-negative breast cancer[J].Curr Breast Cancer Rep, 2015, 7(4):224-231.
[16] 孙向洁, 杨文涛.免疫组织化学在乳腺癌分子分型中的作用及目前存在的问题[J].中国癌症杂志, 2019, 29(3):161-165.
[17] PREUSSER M, HOEFTBERGER R, WOEHRER A, et al.Prognostic value of Ki67 index in anaplastic oligodendroglial tumours-a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group[J].Histopathology, 2012, 60(6):885-894.
[18] GOLDHIRSCH A, WINTER E P, COATES A S, et al.Personalizing the treatment of women with early breast cancer:highlights of the St.Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol, 2013, 24(9):2206-2223.
[19] ABRAMSON V G, LEHMANN B D, BALLINGER T J, et al.Subtyping of triple-negative breast cancer:implications for therapy[J].Cancer, 2015, 121(1):8-16.
[20] 钟铭强, 蓝必全, 冯国生.转移性三阴性乳腺癌靶向治疗的研究进展[J].广西医学, 2021, 43(3):367-372, 389.
[21] MCDERMOTT D F, SOSMAN J A, SZNOL M, et al.Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma:long-term safety, clinical activity, and immunecorre lates from a phase Ⅰa study[J].J Clin Oncol, 2016, 34(8):833-842.
[22] SCHMID P, ADAMS S, RUGO H S, et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med, 2018, 379(22):2108-2121.